This week, Calico’s chief executive Art Levinson revealed that he is beginning to recruit a superstar genetics team.
Editor’s Pick VentureBeat caught up with some of Silicon Valley’s power players to gauge their opinions on Google’s new initiative to prolong human life.
Cambridge, Mass., based Sirtris Pharmaceuticals raised at least $60 million in an initial offering, after pricing six million shares in the middle of its anticipated range of $9 to $11 apiece. The company is developing drugs that aim to mimic the health benefits of calorie-restricted diets, which have been shown to greatly extend life in a variety of animals. Sirtris’ drugs are designed to activate a protein called Sirt1, which some scientists believe may be responsible for the beneficial effects of caloric restriction.